FDA OKs Biohaven’s Sublingual BHV-0223 for Clinical Investigation

FDA OKs Biohaven’s Sublingual BHV-0223 for Clinical Investigation

The U.S. Food and Drug Administration (FDA) has given the green light to Biohaven Pharmaceuticals to advance sublingual BHV-0223, which regulates glutamate communication between neurons, into clinical trials for amyotrophic lateral sclerosis (ALS) patients. The FDA’s  permission to go ahead with the study followed Biohaven’s submission of an investigational new drug…

An ALS Documentary: ‘Mr. Connolly Has ALS’

https://vimeo.com/216244227 This film by Dan Habib is all about the extraordinary life of high school principal Gene Connolly. Connolly was the much-loved principal of Concord High School for 14 years before he was struck by amyotrophic lateral sclerosis (ALS) in 2014. MORE: Explaining the progression…

Understanding How Plants Eliminate Protein Folding Could Help with ALS Research

In some neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), nerve cells fold their proteins incorrectly, leading to cell death. Using plants, researchers discovered that when defective proteins accumulate in chloroplasts – a plant’s cellular compartment where photosynthesis occurs – it generates a distress signal that produces reparative proteins to…

Motor Neurons’ Role in ALS

In this short film from Project ALS (a research-based non-profit organization founded by Jenifer Estes), the role motor neurons play in amyotrophic lateral sclerosis (ALS) is discussed. MORE: Study validates the use of social cognitive measure in ALS patients The computer-generated graphics explains what happens when…

Lessons Learned from Echo Show

Recently, thanks to my ALS News Today publisher, I had the exciting opportunity to test out an Echo Show. Why would I rate that as exciting? Well, we already owned an Amazon Echo (tower-type) device, but with my ALS-affected voice, I was batting zero activating it.

BrainStorm Expands Patent Coverage of NurOwn Therapy for ALS, Parkinson’s

BrainStorm Cell Therapeutics is expanding the patent portfolio that protects its NurOwn technology for the treatment of several diseases affecting the central nervous system. The latest U.S. patent claim includes Parkinson’s disease and ALS (amyotrophic lateral sclerosis). The announcement by BrainStorm follows a Notice of Allowance issued by…